Ameritas Advisory Services’s Takeda Pharmaceutical TAK Stock Holding History

Ameritas Advisory Services’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-65	Closed	-$952	–	1967
2025 Q3	$952	Sell	65 -45	-41%	-$668	﹤0.01%	2065
2025 Q2	$1.7K	Buy	+110	New	+$1.63K	﹤0.01%	2522
2023 Q2	–	Sell	-134	Closed	-$2.23K	–	2307
2023 Q1	$2.23K	Buy	+134	New	+$2.13K	﹤0.01%	2363

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameritas Advisory Services's TAK Position: Q4 2025 in Review

Ameritas Advisory Services sold out of Takeda Pharmaceutical (TAK) in Q4 2025, closing a stake of 65 shares — an estimated $952 sold.

Ameritas Advisory Services first reported a position in TAK in Q1 2023 and held it in 3 quarters. The position peaked at $2.23K in Q1 2023. 349 funds tracked by Wall St. Rank hold TAK as of Q4 2025.

Ameritas Advisory Services reported no remaining Takeda Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Ameritas Advisory Services sold 65 Takeda Pharmaceutical shares in Q4 2025, an estimated $952.
Ameritas Advisory Services first reported a position in Takeda Pharmaceutical in Q1 2023 and held it in 3 quarters.
Ameritas Advisory Services's Takeda Pharmaceutical position peaked at $2.23K in Q1 2023.
349 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2025.

Based on Ameritas Advisory Services's 13F filing for Q4 2025, filed 4 Feb 2026.